Targeting IDH1: Long-Term Efficacy and Tolerance of Ivosidenib in Advanced Chondrosarcoma
DOI:
https://doi.org/10.20344/amp.24606Keywords:
Chondrosarcoma/drug therapy, Chondrosarcoma/genetics, Isocitrate Dehydrogenase/genetics, Ivosidenib/therapeutic use, Molecular Targeted Therapy, MutationAbstract
Around 20% of primary bone malignancies are chondrosarcomas. Advanced or recurrent conventional chondrosarcomas are typically resistant to chemotherapy and radiotherapy and overall survival remains poor, highlighting the need for other therapeutic options. We present two cases of metastatic chondrosarcoma with isocitrate dehydrogenase 1 (IDH1) mutation treated with ivosidenib. In case 1, a 70-year-old woman with recurrent metastatic grade 2 chondrosarcoma achieved well-tolerated, durable stable disease for 12 months in second line (no response to conventional first line chemotherapy). In case 2, a 63-year-old man with recurrence of grade 2 chondrosarcoma maintained stable disease for 16 months on ivosidenib first line. In both cases, there were no relevant toxicities with no need for dose adjustments. These cases highlight the usefulness of ivosidenib as a targeted therapeutic option for patients with metastatic or recurrent unresectable chondrosarcomas with IDH1 mutation. Long-term efficacy with very good tolerance was achieved.
Downloads
References
Tap WD, Cote GM, Burris H, Gore L, Elias A, Beeram M, et al. Phase I study of the mutant IDH1 inhibitor ivosidenib: long-term safety and clinical activity in patients with conventional chondrosarcoma. Clin Cancer Res. 2025;31:2108–14. DOI: https://doi.org/10.1158/1078-0432.CCR-24-4128
Gazendam A, Popovic S, Parasu N, Ghert M. Chondrosarcoma: a clinical review. J Clin Med. 2023;12:2506. DOI: https://doi.org/10.3390/jcm12072506
Amary MF, Bacsi K, Maggiani F, Damato S, Halai D, Berisha F, et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol. 2011;224:334–43. DOI: https://doi.org/10.1002/path.2913
Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the common terminology criteria for adverse Events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr. 2021;112:90–2. DOI: https://doi.org/10.1016/j.adengl.2019.05.021
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228–47. DOI: https://doi.org/10.1016/j.ejca.2008.10.026
Landuzzi L, Ruzzi F, Lollini PL, Scotlandi K. Chondrosarcoma: new molecular insights, challenges in near-patient preclinical modeling, and therapeutic approaches. Int J Mol Sci. 2025;26:1542. DOI: https://doi.org/10.3390/ijms26041542
Tlemsani C, Larousserie F, De Percin S, Audard V, Hadjadj D, Chen J, et al. Biology and management of high-grade chondrosarcoma: an update on targets and treatment options. Int J Mol Sci 2023;24:1361. DOI: https://doi.org/10.3390/ijms24021361
Tian W, Zhang W, Wang Y, Jin R, Wang Y, Guo H, et al. et al. Recent advances of IDH1 mutant inhibitor in cancer therapy. Front Pharmacol. 2022;13:982424. DOI: https://doi.org/10.3389/fphar.2022.982424
Casak SJ, Pradhan S, Fashoyin-Aje LA, Ren Y, Shen YL, Xu Y, et al. et al. FDA approval summary: ivosidenib for the treatment of patients with advanced unresectable or metastatic, chemotherapy refractory cholangiocarcinoma with an IDH1 mutation. Clin Cancer Res. 2022;28:2733–7. DOI: https://doi.org/10.1158/1078-0432.CCR-21-4462
Wagner AJ, Stacchiotti S, Debruyne C, Salawu A, Blay JY, Campos F, et al. Phase 3 study of ivosidenib vs placebo in locally advanced or metastatic IDH1-mutant conventional chondrosarcoma untreated or previously treated with 1 systemic treatment regimen (CHONQUER). J Clin Oncol. 2025;43:TPS11582. DOI: https://doi.org/10.1200/JCO.2025.43.16_suppl.TPS11582
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Acta Médica Portuguesa
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.
It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.
Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.
After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.
